Inceptionr LLC Takes Position in Kymera Therapeutics, Inc. $KYMR

Inceptionr LLC bought a new stake in Kymera Therapeutics, Inc. (NASDAQ:KYMR) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 6,468 shares of the company’s stock, valued at approximately $282,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. GSA Capital Partners LLP boosted its holdings in Kymera Therapeutics by 6.8% during the first quarter. GSA Capital Partners LLP now owns 31,537 shares of the company’s stock valued at $863,000 after purchasing an additional 1,997 shares in the last quarter. Vanguard Group Inc. raised its holdings in shares of Kymera Therapeutics by 7.0% in the 1st quarter. Vanguard Group Inc. now owns 5,231,392 shares of the company’s stock worth $143,183,000 after buying an additional 344,080 shares in the last quarter. Invesco Ltd. lifted its position in shares of Kymera Therapeutics by 36.9% during the 1st quarter. Invesco Ltd. now owns 42,075 shares of the company’s stock worth $1,152,000 after buying an additional 11,343 shares during the period. Nuveen LLC acquired a new stake in Kymera Therapeutics in the 1st quarter valued at $3,920,000. Finally, Russell Investments Group Ltd. grew its position in Kymera Therapeutics by 40.0% in the first quarter. Russell Investments Group Ltd. now owns 82,507 shares of the company’s stock valued at $2,258,000 after acquiring an additional 23,584 shares during the period.

Analysts Set New Price Targets

Several research firms have issued reports on KYMR. Morgan Stanley reiterated an “overweight” rating and set a $73.00 price objective on shares of Kymera Therapeutics in a research note on Tuesday, November 4th. Royal Bank Of Canada started coverage on shares of Kymera Therapeutics in a report on Tuesday, September 16th. They issued an “outperform” rating and a $70.00 target price on the stock. Wall Street Zen upgraded shares of Kymera Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, November 8th. UBS Group set a $90.00 price target on shares of Kymera Therapeutics and gave the company a “buy” rating in a research report on Wednesday. Finally, Truist Financial upped their price objective on shares of Kymera Therapeutics from $68.00 to $80.00 and gave the stock a “buy” rating in a research note on Wednesday. Two research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $71.35.

Insider Transactions at Kymera Therapeutics

In other news, Director Jeffrey W. Albers sold 5,000 shares of the business’s stock in a transaction on Monday, October 13th. The stock was sold at an average price of $59.19, for a total transaction of $295,950.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Nello Mainolfi sold 30,000 shares of the firm’s stock in a transaction dated Tuesday, September 16th. The shares were sold at an average price of $49.00, for a total value of $1,470,000.00. Following the completion of the transaction, the chief executive officer owned 660,482 shares in the company, valued at approximately $32,363,618. This represents a 4.34% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 206,910 shares of company stock worth $11,402,648 in the last quarter. 16.01% of the stock is owned by corporate insiders.

Kymera Therapeutics Trading Up 2.7%

KYMR opened at $69.67 on Friday. Kymera Therapeutics, Inc. has a 1-year low of $19.44 and a 1-year high of $68.80. The stock has a market capitalization of $5.01 billion, a PE ratio of -19.41 and a beta of 2.32. The firm has a 50-day moving average price of $60.16 and a two-hundred day moving average price of $48.66.

Kymera Therapeutics (NASDAQ:KYMR) last announced its earnings results on Tuesday, November 4th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.19). The company had revenue of $2.76 million for the quarter, compared to analyst estimates of $23.15 million. Kymera Therapeutics had a negative return on equity of 32.92% and a negative net margin of 674.81%. On average, research analysts predict that Kymera Therapeutics, Inc. will post -2.79 EPS for the current year.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.